FOSVESET

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H44N3O14P
Molecular Weight	737.6879
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN(CCN(CC(O)=O)CC(O)=O)C[C@H](COP(O)(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC(O)=O)CC(O)=O

InChI

InChIKey=NZLPWFTXPYJYSS-AREMUKBSSA-N

InChI=1S/C33H44N3O14P/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48)/t26-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C33H44N3O14P
Molecular Weight	737.6879
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf
Curator's Comment: description was created based on several sources, including: http://radiopaedia.org/articles/gadofosveset-trisodium-1

Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography (MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels. Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood. The extended acquisition time and increased relaxivity of gadofosveset allows for longer steady-state acquisition times, and potentially submillimeter voxels. Overlay of veins in steady-state MR angiography is less of a problem in multiplanar reformats with this level of resolution. This is particularly promising for MR evaluation of the peripheral vasculature. In the United States, gadofosveset is FDA-approved only for use in aortoiliac disease, with other uses being off-label. It currently does not have a role in hepatic imaging.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serum albumin 18 Target ID: P02768\|\|\|Q86YG0 Gene ID: 213.0 Gene Symbol: ALB Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf	Binding Agent 1076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Aortoiliac occlusive disease 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf	Diagnostic		Approved 8583	ABLAVAR Approved Use ABLAVAR Injection is a gadolinium-based contrast agent indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. Launch Date 2008

C_max

Value	Dose	Analyte	Population
98.3 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.05 mmol/kg single, intravenous dose: 0.05 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
129 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.075 mmol/kg single, intravenous dose: 0.075 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
151 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
962 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.05 mmol/kg single, intravenous dose: 0.05 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1327 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.075 mmol/kg single, intravenous dose: 0.075 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1435 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
13.9 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.05 mmol/kg single, intravenous dose: 0.05 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
15 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.075 mmol/kg single, intravenous dose: 0.075 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
14.9 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:	GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
12.6% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf#page=7	0.03 mmol/kg single, intravenous dose: 0.03 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GADOFOSVESET plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

PubMed

Title	Date	PubMed
Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.	2014-12	24852287

Patents

Sample Use Guides

In Vivo Use Guide

Administer ABLAVAR (gadofosveset trisodium) Injection by an intravenous bolus, manually or by power injection, at a dose of 0.12 mL/kg body weight (0.03 mmol/kg) over a period of time up to 30 seconds followed by a 25-30 mL normal saline flush.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:27 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:27 GMT 2025`
Record UNII	5WBR90FN3H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOSVESET

Official Name

English

MS-325168A

Preferred Name

English

FOSVESET [USAN]

Common Name

English

MS325168A

Code

English

fosveset [INN]

Common Name

English

N-[2-[Bis(carboxymethyl)amino]ethyl]-N-[(R)-2-[bis(carboxymethyl)amino]-3-hydroxypropyl]glycine, 4,4-diphenylcyclohexyl hydrogen phosphate (ester)

Systematic Name

English

2-OXA-6,9-DIAZA-1-PHOSPHAUNDECAN-11-OIC ACID, 4-(BIS(CARBOXYMETHYL)AMINO)-6,9-BIS(CARBOXYMETHYL)-1-((4,4-DIPHENYLCYCLOHEXYL)OXY)-1-HYDROXY-, 1-OXIDE

Common Name

English

FOSVESET [VANDF]

Common Name

English

Code System Code Type Description

SMS_ID

100000087355